Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach